Illinois Medicaid spending on GLP-1 drugs

How much did Illinois Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $305.6 million for GLP-1 drugs paid through Illinois Medicaid in 2025, across at least 288,522 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 65 rows of 287, so these figures are floors.

Pharmacies were reimbursed at least $55.3 million for GLP-1 drugs paid through Illinois Medicaid in 2026 (quarter 1 only, as posted so far), across at least 52,093 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 11 rows of 71, so these figures are floors.

By year and ingredient

2020at least $3,845,460No data$34,426,154at least $7,978,932at least $6,742,299$157,894at least $115,325at least $53,266,064
2021at least $10,233,857No dataat least $71,892,496at least $16,017,576at least $5,798,751at least $224,937at least $108,671at least $104,276,287
2022at least $25,991,020at least $399,839at least $72,854,897at least $109,510,100at least $2,192,442at least $445,946at least $120,845at least $211,515,088
2023at least $31,242,373at least $5,038,521at least $59,250,775at least $201,454,041at least $440,089at least $137,224at least $21,155at least $297,584,178
2024at least $58,180,925at least $22,878,617at least $22,722,320at least $187,285,254at least $81,180at least $78,308Suppressedat least $291,226,604
2025at least $62,762,987at least $41,516,607at least $9,115,032at least $192,098,531at least $16,007at least $43,498Suppressedat least $305,552,662
2026 (Q1)at least $10,541,935at least $9,031,641at least $1,151,122at least $34,553,604SuppressedSuppressedSuppressedat least $55,278,302

By product, 2025

Ozempicat least $32,634,168at least 30,5565 of 29
Rybelsusat least $28,675,814at least 23,6621 of 25
Wegovyat least $1,453,005at least 1,1091 of 21
Mounjaroat least $39,483,698at least 34,4355 of 53
Zepboundat least $2,032,908at least 1,9373 of 21
Liraglutide (generic name listing)at least $8,011,145at least 16,5148 of 48
SaxendaSuppressedSuppressed3 of 3
Victozaat least $1,103,887at least 1,4177 of 16
Trulicityat least $192,098,531at least 178,82011 of 45
Bydureonat least $16,007at least 203 of 4
ByettaSuppressedSuppressed6 of 6
Exenatide (generic name listing)SuppressedSuppressed3 of 3
Soliquaat least $43,498at least 523 of 7
XultophySuppressedSuppressed6 of 6

By quarter, 2025

Q1 2025at least $75,909,404at least 69,41416 of 69
Q2 2025at least $75,502,457at least 71,74221 of 75
Q3 2025at least $76,952,517at least 73,47414 of 70
Q4 2025at least $77,188,283at least 73,89214 of 73

By quarter, 2026 (posted so far)

Q1 2026at least $55,278,302at least 52,09311 of 71

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.